2021 at a glance

766 m

Patients reached

with Novartis medicines

21

Major approvals (US, EU, Japan, China)

including two new molecular entity approvals from the US Food and Drug Administration (FDA)

3

Breakthrough therapy designations

from the FDA

51.6 bn

Net sales

growing 4% in constant currencies from 2020 (USD)

16.6 bn

Core operating income

growing 6% in constant currencies from 2020 (USD)

7.4 bn

Total dividends paid 

to shareholders (USD)

71 bn

Treatments supplied

through Novartis facilities

78

Employee engagement

score in Q4 (out of 100), 5 points higher than the industry benchmark

300 000

Patients using AI Nurse

our cardiovascular disease app in China

1 bn

Antimalarial treatments

delivered in the past two decades in endemic countries, more than 90% of which were supplied without profit

40 m

Doses produced

of the Pfizer-BioNTech vaccine for COVID-19

-34%

Greenhouse gas emissions

reduced vs. 2016 baseline (Scope 1 and Scope 2)

Ratings and recognition

Access to Medicine Index

Novartis ranked second in 2021, retaining our 2018 position

Dow Jones Sustainability World Index

Novartis was also included in the DJSI Europe Index

Sustainalytics

Novartis leads in the pharmaceutical subindustry group

World’s 25 Best Workplaces™

Novartis is proud to be included in Fortune’s World’s 25 Best Workplaces™ list

Bloomberg Gender-Equality Index

Novartis was included for the second year in a row